Effects of trimetazidine on interleukin-2 and interleukin-8 concentrations in patients with coronary artery disease

Can J Physiol Pharmacol. 2017 Jun;95(6):759-762. doi: 10.1139/cjpp-2016-0424. Epub 2017 Feb 26.

Abstract

Trimetazidine (TMZ) exhibits metabolic and cardioprotective effects. The aim of this study was to assess the effects of TMZ on interleukin-2 (IL-2) and interleukin-8 (IL-8) serum concentrations in 156 patients with stable coronary artery disease. They underwent a treadmill exercise test (TET) before and after 3 months of TMZ treatment. IL-2 and IL-8 concentrations were determined before and after each TET. Before treatment, TET did not influence IL-2 concentrations, whereas IL-8 concentrations increased. TMZ treatment led to a decrease in IL-2 concentrations before TET, as well as it prevented the increase of IL-8 following the second TET. Obtained results confirmed the improvement in TET performance during TMZ treatment and they revealed a significant influence of TMZ on IL-2 and IL-8 concentrations both before and after TET. These changes may reflect potential anti-inflammatory effects of TMZ.

Keywords: coronaropathie; coronary artery disease; interleukin-2; interleukin-8; interleukine-2; interleukine-8; trimetazidine; trimétazidine.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Coronary Artery Disease / blood*
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / physiopathology
  • Exercise / physiology
  • Female
  • Humans
  • Interleukin-2 / blood*
  • Interleukin-8 / blood*
  • Male
  • Middle Aged
  • Stress, Physiological / drug effects
  • Trimetazidine / pharmacology*
  • Trimetazidine / therapeutic use

Substances

  • Interleukin-2
  • Interleukin-8
  • Trimetazidine